Evercore, Capital One
Hosted on MSN29d
Evercore ISI lifts CRISPR stock rating, target to $99The new price target of $99 takes into account the potential of CRISPR Therapeutics' in vivo programs, CTX320 and CTX310. Evercore ISI has assigned a probability of success (POS) of 10% and 5% to ...
Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6, citing discounted valuation, a potential industry turnaround ...
Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm ...
Hosted on MSN1mon
Evercore ISI lifts Knight Transportation target to $62Evercore ISI has revised its 2025 EPS estimate for Knight Transportation to $2.06 from $2.00 and the 2026 forecast to $3.27 from $3.20. Chappell noted that while Knight Transportation has made ...
CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh Schafer examine what the analysts say about the biotech company on ...
Albertsons Companies (NYSE:ACI – Get Free Report) had its target price lifted by research analysts at Evercore ISI from $21.00 to $22.00 in a report issued on Tuesday,Benzinga reports. The brokerage ...
On Friday, Evercore ISI analyst Stephen Richardson raised the rating for Canadian Natural Resources Limited (TSX:CNQ:CN) (NYSE: CNQ) from In Line to Outperform, while maintaining the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results